Key terms
About DARE
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DARE news
Apr 23
8:11am ET
Dare Bioscience announces it will receive payment of $1M under grant agreement
Apr 19
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Apr 17
12:56pm ET
Dare Bioscience downgraded to Hold from Buy at Brookline
Apr 11
8:06am ET
Dare Bioscience announces publication of data from Ovaprene study
Apr 03
2:50pm ET
Analysts Are Bullish on These Healthcare Stocks: BiomX (PHGE), Daré Bioscience (DARE)
Apr 01
6:20am ET
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Imunon (IMNN)
Mar 30
2:00am ET
Daré Bioscience’s Reverse Stock Split: Navigating the Risks of Market Perception and Shareholder Liquidity
Mar 29
6:56pm ET
Dare Bioscience files to sell 15M shares of common stock for holders
Mar 29
6:56pm ET
Dare Bioscience files $200M mixed securities shelf
Mar 28
8:06am ET
Dare Bioscience reports FY23 EPS (35c), consensus (38)
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
8:18am ET
Dare Bioscience to present additional data from Phase 2b RESPOND study
Feb 01
3:16pm ET
Buy Rating Affirmed: Daré Bioscience’s Regulatory Progress and Strategic Financing Underpin Future Growth
Feb 01
6:17am ET
Buy Rating Affirmed: Daré Bioscience’s Promising Market Potential and Positive FDA Engagement
Jan 31
8:02am ET
Dare Bioscience announces completion of end-of-Phase 2 meeting with U.S. FDA
Jan 27
4:36am ET
Daré Bioscience Announces Regulation FD Disclosure Update
Jan 27
4:36am ET
Daré Bioscience Announces Executive Team Transition and Board Reduction
Jan 26
4:33pm ET
Dare Bioscience CFO Walters-Hoffert to retire
No recent press releases are available for DARE
DARE Financials
Key terms
Ad Feedback
DARE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DARE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range